Unilife — FY2010 Earnings Presentation
19 slides from Unilife's earnings presentation, Aug 31, 2010
Slide 1: 4th Quarter and Fiscal Year 2010 Conference Call
1 4th Quarter and Fiscal Year 2010 Conference Call August 30, 2010
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward- looking statements are based on management's beliefs and assumptions and on information currently available to our m
Slide 3: Unilife's Opportunity
3 Portfolio poised to capitalize on mandated move to safety World's only pre-filled syringe with passive, integrated safety $40 million validating partnership with sanofi-aventis Accelerating talks with many other pharmaceutical leaders Highly experienced team with deep industry expertise Now buildi
Slide 4: Preliminary Financial Data
4 Preliminary Financial Data Richard Wieland Chief Financial Officer
Slide 5: Preliminary Financial Data - 12 months
5 Preliminary Financial Data - 12 months Total revenues of $11.4m in Fiscal 2010 Sanofi industrialization revenue decreased from $13.6m to $6.3m due to timing of milestones reached Net loss of $29.7m ($0.64 per diluted share) in Fiscal 2010 Stock compensation increased $7m (including $4.3m for R&D),
Slide 6: Preliminary Financial Data - 12 months adjusted net loss
6 Preliminary Financial Data - 12 months Adjusted net loss of $14.5m ($0.31 per diluted share) in Fiscal 2010 Non-cash items were $15.2m including share-based compensation expense, depreciation and amortization, interest expense and certain nonrecurring costs associated with the redomiciliation and
Slide 7: Preliminary Financial Data - 4th Quarter
7 Preliminary Financial Data - 4th Quarter Revenues of $2.7m in Fiscal 2010 Fourth Quarter Sanofi industrialization revenue decreased from $6.3m to $1.3m due to timing of milestones reached Net loss of $9.7m ($0.18 per diluted share) in Fiscal 2010 Fourth Quarter Stock compensation increased $2.9m R
Slide 8: Preliminary Financial Data - 4th Quarter adjusted net loss and balance sheet
8 Preliminary Financial Data - 4th Quarter Adjusted net loss of $5.7m ($0.11 per diluted share) in Fiscal 2010 Fourth Quarter Non-cash items were $4.0m including share-based compensation expense, depreciation and amortization, interest expense and certain nonrecurring costs associated with the redom
Slide 9: Fiscal 2010 Highlights
9 Fiscal 2010 Highlights Alan Shortall Chief Executive Officer
Slide 10: Outline of Key Expenditures - FY 2010
10 Outline of Key Expenditures - FY 2010 Redomiciliation to the U.S Listed common stock on NASDAQ; CDIs on ASX Growth in personnel to support key projects Industrialization program for Unifill(tm) syringe Completion of Unitract(tm)1mL syringe production systems Research and development for pipeline
Slide 11: Strengthened Board and Management Team
11 Strengthened Board and Management Team Appointed three new independent U.S. based Directors John Lund, CPA (Non-Executive Director) Mary Kate Wold, JD (Non-Executive Director) Marc Firestone, JD (Non-Executive Director) Average of 25 years experience within management team Richard Wieland, BA, MB
Slide 12: Building Operational Infrastructure
12 Building Operational Infrastructure Renderings of new facility State-of-the-art Facility in York, PA Construction commenced during winter of 2009 / 2010 Clean rooms, air-conditioning and offices now being installed Remains fully on schedule - ready for operations in late-2010
Slide 13: Building Operational Infrastructure - Renderings of completed facility
13 Renderings of completed facility December 2009 August 26, 2010 July 19, 2010 Building Operational Infrastructure State-of-the-art Facility in York, PA
Slide 14: Unitract 1mL syringes
14 U.S. made stock approved in U.S, EU, Canada and Australia 510k FDA submission for Unitract(tm) TB variant pending Initial supplies to Europe, Haiti Appointed exclusive partners for Japan, China, Taiwan and India Advanced discussions for other markets including U.S. and European countries Unitract
Slide 15: The Unifill Syringe - Sanofi-aventis Agreements
15 Industrialization agreement Supports commercialization program for the Unifill(tm) syringe Program started in July 2008 All milestones met to-date Exclusivity List of Therapeutic Drug Classes Vaccines, antithrombotic agents Four smaller sub-groups Sanofi-aventis Agreements The Unifill(tm) Syringe
Slide 16: The Unifill Syringe - Competitive comparison
16 Secondary container Extra steps between filling and shipment 60%+ larger size Increased costs Invasive appearance Bulky handling and disposal Primary container Integrated into fill- finish systems Similar size to normal prefilled Streamlines supply chain Intuitive use Compact disposal Unique vehi
Slide 17: Other Pharmaceutical Relationships
17 Other Pharmaceutical Relationships Ongoing discussions with multiple interested parties Vast opportunity outside of therapeutic areas already retained Indicative table of marketed and pipeline drugs (83) that are potential UnifillTM Syringe targets Sanofi- aventis Additional pharmaceutical compan
Slide 18: Unifill syringes positioned to extend product lifecycles and protect revenue streams
18 UnifillTM syringes strongly positioned to help extend product lifecycles and protect revenue streams Examples of Blockbuster Prefilled Drugs LMWH $4B Arthritis $7B MS $2.2B Immuno $1.2B MS $2.5B MS $3B Immuno $3.5B Under pressure from generic or biosimilar competition
Slide 19: Questions
uniuire®? Questions